Disease Areas
Diabetes
Obesity
Cardiovascular Disease (CVD)
Chronic Kidney Disease (CKD)
Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Neurodegenerative Diseases
Haemophilia
Sickle Cell Disease
Primary Hyperoxaluria
Growth Hormone Disorders
Hormone Replacement Therapy
Congresses
Scientific Publications
IME
Search Science Hub
Register
Login
My Account
Welcome to Novo Nordisk Science Hub
Are you a healthcare professional?
No
Yes
Congresses
The Obesity Society (Obesity Week 2025)
Lower Real-World Risk of Cardiovascular Events With Semaglutide 2.4 mg in People with Risk Factors for Atherosclerotic Cardiovascular Disease: Results from SCORE – Primary Prevention Population study
The Obesity Society (Obesity Week 2025)
Authors
:
Affiliations
View Details
Hide Details
{{ getPageNum(PDFPage) }}